| [1］Skorski T.Genetic mechanisms of chronic myeloid leukemia blastic transformation［J］.Curr Hematol Malig Rep，2012，7(2)：87-93. [2］Santos FP，Kantarjian H，Quintás-Cardama A，et al.Evolution of therapies for chronic myelogenous leukenia［J］.Cancer J，2011，17(6)：465-476. [3］O’Brien SG，Guilhot F，Larson RA，et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia［J］.N Engl J Med，2003，348(11)：994-1004. [4］Kantarjian H，O’Brien S，Jabbour E，et al.Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy：a single-institution historical experience［J］.Blood，2012，119(9)：1981-1987. [5］Jabbour EJ，Kantarjian H，Eliasson L，et al.Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia［J］.Am J Hematol，2012，7(7)：687-691. [6］Sabate E.Adherence to long-term therapies：evidence for action［C］.Geneva，WHO，2003. [7］Ruddy K，Mayer E，Partridge A.Patient adherence and persistence with oral anticancer treatment［J］.CA Cancer J Clin，2009，59：56-66. [8］Marin D，Bazeos A，Mahon FX，et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib［J］.J Clin Oncol，2010，28(14)：2381-2388. [9］Osterberg L，Blaschke T.Adherence to medication［J］.N Engl J Med，2005，353(5)：487-497. [10］Rezende VM，Rivellis AJ，Gomes MM，et al.Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia：validation and application of a new analytical method to monitor treatment compliance［J］.Rev Bras Hematol Hemoter，2013，35(2)：103-108. [11］Yoshida C，Komeno T，Hori M，et al.Adherence to the standard dose of imatinib，rather than dose adjustment based on its plasma concentration，is critical to achieve a deep molecular response in patients with chronic myeloid leukemia［J］.Int J Hematol，2011，93(5)：618-623. [12］Cramer JA，Roy A，Burrell A，et al.Medication compliance and persistence：terminology and definitions［J］.Value Health，2008，11(1)：44-47. [13］Daouphars M，Ouvry M，Lenain P，et al.Preliminary validation of self-assessment tool to measure imatinib adherence in patients withchronic myeloid leukemia［J］.Pharmacotherapy，2013，33：152-156. [14］de Almeida MH，Pagnano KB，Vigorito AC，et al.Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia：a Brazilian single-center cohort［J］.Acta Haematol，2013，130：16-22. [15］Ibrahim AR，Eliasson L，Apperley JF，et al.Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy［J］.Blood，2011，117(14)：3733-3736. [16］Dos Reis SR，Quixadá AT，Nunes ST，et al.Adherence to treatment with imatinib in chronic myeloid leukemia a study of the first decade of responses obtained at a Brazilian hospital［J］.Rev Bras Hematol Hemoter，2013，35(3)：174-179. [17］Noens L，van Lierde MA，De Bock R，et al.Prevalence，determinants，and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia：the ADAGIO study［J］.Blood，2009，113(22)：5401-5411. [18］Ganesan P，Sagar TG，Dubashi B，et al.Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia［J］.Am J Hematol，2011，86(6)：471-474. [19］Chen TC，Chen LC，Huang YB，et al.Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan［J］.Int J Clin Pharm，2014，36(1)：172-181. [20］Wu EQ，Johnson S，Beaulieu N，et al.Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients［J］.Curr Med Res Opin，2010，26(1)：61-69. [21］Darkow T，Henk HJ，Thomas SK，et al.Treatment interruptions and non-adherence with imatinib and associated healthcare costs：a retrospective analysis among managed care patients with chronic myelogenous leukaemia［J］.Pharmacoeconomics，2007，25：481-496. [22］Efficace F，Baccarani M，Rosti G，et al.Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia：an observational patient-centered outcome study［J］.Br J Cancer，2012，107(6)：904-909. [23］梁蓉，陈协群，白庆咸，等.甲磺酸伊马替尼治疗慢性粒细胞白血病的临床观察［J］.中华肿瘤防治杂志，2011，18(14)：1121-1124. [24］Moon JH，Sohn SK，Kim SN，et al.Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemiapatients［J］.Med Oncol，2012，29(2)：1179-1185. [25］Chen LC，Chen TC，Huang YB，et al.Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemiaoutpatients［J］.Int J Clin Pharm，2014，36(1)：120-127. |
